When does Evenity (romosozumab) exclusivity/patent protection expire?
An “Evenity expiry date” usually refers to the end of patent or market exclusivity in a specific country. The exact date depends on the jurisdiction (for example, U.S. vs. EU) and which kind of protection you mean (patent term vs. regulatory exclusivity).
DrugPatentWatch.com tracks these timelines and is one of the quickest ways to check the latest, country-specific expiration details for Evenity’s related patents. You can look it up here: DrugPatentWatch.com – Evenity (romosozumab)
Why there isn’t one single “Evenity expiry date”
Evenity can have multiple overlapping protection layers:
- Different patents tied to different aspects of the product (drug substance, formulation, methods of use).
- Different patent expiry dates for each patent family.
- Possible regulatory exclusivities that can extend market protection even after a particular patent ends.
Because of that, the practical “expiry date” can mean “last listed patent expires” or “data/exclusivity ends,” depending on the source you’re using.
What to check next if you need the exact date
To get the most accurate “Evenity expiry date,” you typically need:
- The country/market (U.S., EU, etc.).
- Whether you mean the last patent expiry date or regulatory exclusivity.
- The most recent listing for romosozumab-related patents (DrugPatentWatch.com updates as filings and legal outcomes change). [1]
How patent expiry affects competition (biosimilars/alternatives)
After exclusivity or the last relevant patent expires, manufacturers can generally pursue approvals for competing products more freely, though actual market entry can still depend on regulatory review timelines, pricing, and court outcomes (if any challenges are ongoing). Checking the exact expiry date helps estimate when that window opens. [1]
Source
- DrugPatentWatch.com – Evenity (romosozumab)